Research
Hormonal
Chronic calcium deficiency resulting from inadequate intake or poor intestinal absorption causes reduced bone mass and osteoporosis by triggering parathyroid hormone (PTH)-mediated bone resorption.
Ensure you get enough calcium from your diet (dairy, fortified foods) to support bone health. If you are postmenopausal or elderly, calcium supplementation may help reduce bone loss, but it is not a cure-all and works best when combined with Vitamin D and adequate baseline intake.
GoodSupportsHIGH confidence
Chronic Ca deficiency resulting from inadequate intake or poor intestinal absorption is one of several important causes of reduced bone mass and osteoporosis.
Why this rating
The paper is a review citing multiple intervention and cross-sectional studies, though it notes debates on the magnitude of effects.
Source
Calcium intake, calcium bioavailability and bone health
Cashman K.D.* · British Journal Of Nutrition · 2002
DOI 10.1079/bjnbjn/2002534
narrative_reviewCited 263×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Combined supplementation with calcium and vitamin D significantly reduces hip and non-vertebral fracture rates in elderly women and men, primarily by correcting Vitamin D status and reducing serum PTH levels.Good
- Non-digestible oligosaccharides (NDOs) such as inulin and oligofructose increase calcium absorption in adolescents and postmenopausal women, but not necessarily in healthy adult men.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →